# To Evaluate the Safety and Pharmacokinetic Characteristics After the Administration of JT-001, JT-002 and JLP-2008

> **NCT06165965** · PHASE1 · COMPLETED · sponsor: **Jeil Pharmaceutical Co., Ltd.** · enrollment: 48 (actual)

## Conditions studied

- Healthy Adult

## Interventions

- **DRUG:** SGLT2 inhibitor

## Key facts

- **NCT ID:** NCT06165965
- **Lead sponsor:** Jeil Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-03
- **Primary completion:** 2022-06-13
- **Final completion:** 2022-06-27
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2023-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06165965

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06165965, "To Evaluate the Safety and Pharmacokinetic Characteristics After the Administration of JT-001, JT-002 and JLP-2008". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06165965. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*